Breadcrumb
[A17-56] Cabozantinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Overview
Overview
| Commission: | Commission awarded on 2017-10-16 by the Federal Joint Committee (G-BA) |
|---|---|
| Status: | Commission completed |
| Department/Division: | Drug Assessment |
| Current document: | 
Extract
of dossier assessment
Further documents |
| Note: | After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website. |
| Contact address: | to the contact form |
| Linked projects: |
[G14-07]
Cabozantinib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)
Status: Commission completed [A18-85] Cabozantinib (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V Status: Commission completed [A18-37] Cabozantinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V Status: Commission completed [A18-18] Cabozantinib (renal cell carcinoma) - Second Addendum to Commission A17-56 Status: Commission completed [A18-13] Cabozantinib (renal cell carcinoma) - Addendum to Commission A17-56 Status: Commission completed [A16-69] Cabozantinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V Status: Commission completed |
Report documents
Report documents
| Published | Document | Size | Type | |
|---|---|---|---|---|
| 2018-01-15 | Extract of dossier assessment | 359 kB |  | |
| 2018-01-15 | Dossier assessment (German version) | 916 kB | |
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Accompanying information
Extract of dossier assessment
Cabozantinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Federal Joint Committee (G-BA)
2018-04-05 A G-BA decision was published.
G-BA documents on this decision
